Advertisement


Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement



Jun
12
Today In Oncology
Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer
Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma
Are There Differences in the Prevalence of Germline Pathogenic Variants in Susceptibility Genes in Black vs White Women With Breast Cancer
Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer KEYNOTE-057
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside